Cohort 5 results presented at the 2022 ASCO Annual Meeting were also positive, with ORR and DCR of 10% and 61%, respectively, and a median DOR of 4.1 months.

What were the highlights of the ASCO GU meeting? Watch this expert interview with Simon Crabb and Petros Grivas to hear their thoughts and opinions on the work presented.

ASCO GU 2022 Axel Bex video Daniel Geynisman (Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA), who discussed the presentation, said that after seeing these data he “will feel more comfortable continuing to use [ICI]/TKI therapy in the neoadjuvant setting in highly select patients,” such as those with a solitary kidney or those with “unresectable disease that you are trying to make resectable.”

ASCO GU 2022 Axel Mereseburger video He reported that, during the first period of the PRESIDE study, 687 chemotherapy-naïve men with mCRPC that had progressed on androgen deprivation therapy received enzalutamide 160 mg/day.

ASCO GU 2022 video template He presented data on 41 patients aged a median of 67 years included in cohort 3 of the phase 2 trial, all of whom had previously received platinum-based chemotherapy (no more than two prior regimens) but were naïve to immune checkpoint inhibitor therapy (ICI).

“The FDA label is broad and we have to be careful not to overextend the use to low-risk patients or non-clear-cell patients although some will debate this,” he remarked. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ASCO Genitourinary Cancers Symposium; San Francisco, California, USA: 17–19 February 2022

Chi therefore concluded that “MAGNITUDE highlights the importance of testing for HRR gene alterations in patients with metastatic CRPC to identify those individuals who optimally benefit from the combination of niraparib plus abiraterone.” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ASCO Genitourinary Cancers Symposium; San Francisco, California, USA: 17–19 February 2022

Supplementing first-line abiraterone acetate with olaparib significantly improves the outcomes of patients with metastatic castration-resistant prostate cancer, show phase 3 data reported at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA.

The final results of rucaparib cohort of the phase II study did not show a significant improvement in progression-free survival (PFS) or overall survival (OS) with the PARP inhibitor versus placebo, delegates were told at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA.

ASCO GU 2022 video: Chris Labaki outlines his study evaluating changes in the screening, diagnosis, and treatment of GU malignancies during COVID-19.

Zibelman concluded that “future follow-up will assess long-term outcomes in this cohort, as well as efficacy in the previously treated cohort, which includes patients who received either prior TKIs or prior [ipilimumab/nivolumab].” medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group ASCO Genitourinary Cancers Symposium; San Francisco, California, USA: 17–19 February 2022

The findings were presented by Jonathan Rosenberg, from Memorial Sloan Kettering Cancer Center in New York, USA, at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA.

“Future studies could evaluate potential synergy of PARP inhibitors in combination with other therapies, such as immune checkpoint inhibitors,” concluded Vignani. medwireNews is an independent medical news service provided by Springer Healthcare Ltd. © 2022 Springer Healthcare Ltd, part of the Springer Nature Group This independent news story was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany ASCO Genitourinary Cancers Symposium; San Francisco, California, USA: 17–19 February 2022

The study findings were simultaneously presented at the 2022 ASCO Genitourinary Cancers Symposium in San Francisco, California, USA.

The activity was especially notable in men with disease positive for androgen receptor (AR) mutations, study author Karim Fizazi (Institut Gustave Roussy, Villejuif, France) told delegates of the 2022 ASCO Genitourinary Cancers Symposium, held in San Francisco, California, USA.

ASCO GU 2022 video: Simon Crabb outlines the results of the rucaparib arm of the ATLANTIS trial of maintenance therapy in patients with metastatic

ASCO GU 2022 video: Axel Bex discusses the NeoAvAx study of avelumab plus axitinib in the neoadjuvant high-risk renal cell carcinoma setting.

ASCO GU 2022 video: Axel Merseburger discusses the results of the PRESIDE trial of enzalutamide rechallenge in metastatic castration-resistant

ASCO GU 2022 video: Roberto Iacovelli presents the ARIES trial of frontline avelumab in cisplatin-ineligible patients with PD-L1-positive advanced